Floatz logo

Tavokinogene Telseplasmid

Cutaneous T Cell Lymphomas (CTCL)

OncoSec Medical Incorporatedgene_therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Cutaneous T Cell Lymphomas (CTCL) cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Tavokinogene Telseplasmid is also rated in:

melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
mycosis fungoidesDormant
CCC
Indicative ·
53 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →